• Five hundred four outpatients suffering from a major depressive episode were randomly assigned to receive either amitriptyline, doxepin, alprazolam, or placebo. The study was conducted in three treatment centers during a six-week period. All three active medications produced significantly more clinical improvement than did placebo, irrespective of the patient's initial anxiety, depression, and psychomotor retardation and irrespective of the patient's assignment to various subtypes of depression, including the DSM-III melancholia subtype. Compared with placebo, sedation was reported more frequently with all three medications, whereas anticholinergic effects were reported more frequently only for the two tricyclic antidepressants, but not for alprazolam.
Rickels K, Feighner JP, Smith WT. Alprazolam, Amitriptyline, Doxepin, and Placebo in the Treatment of Depression. Arch Gen Psychiatry. 1985;42(2):134–141. doi:10.1001/archpsyc.1985.01790250028004
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.